Dropped head syndrome: report of three cases during treatment with a MEK inhibitor.
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Xi
X
Chen
Gary K
GK
Schwartz
Lisa M
LM
DeAngelis
Thomas
T
Kaley
Richard D
RD
Carvajal
D000368:Aged; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors*; D048370:MAP Kinase Kinase 2 / Q000037:antagonists & inhibitors*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology; D009468:Neuromuscular Diseases / Q000139:chemically induced* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D013577:Syndrome; D014604:Uveal Neoplasms / Q000188:drug therapy / Q000201:enzymology; D000098943:Uveal Melanoma
C517975:AZD 6244; D001562:Benzimidazoles; D047428:Protein Kinase Inhibitors; C482128:MAP2K2 protein, human; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; C482125:MAP2K1 protein, human